Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

NORTHBROOK, Ill., May 26 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.  Horizon is seeking FDA approval of DUEXA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.  The PDUFA date for completion of the FDA's review for DUEXA is expected in the first quarter of 2011.

"As the pain and arthritis market continues to grow, safe and effective treatments are desperately needed for physicians and patients concerned about the gastrointestinal impact of NSAIDs," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma.  "We look forward to working closely with the FDA to bring DUEXA to market as quickly as possible.  The filing of the DUEXA NDA brings us one step closer to providing the millions suffering from mild-to-moderate pain and arthritis with a new treatment option."

The DUEXA NDA submission was based on two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), which demonstrated that patients with mild-to-moderate pain treated with DUEXA developed approximately fifty percent less upper gastrointestinal (GI) ulcers) compared to patients treated with ibuprofen alone.   The trials were conducted in the U.S. via a Special Protocol Assessment (SPA) with the FDA and enrolled more than 1,500 patients.  Based on these data, the Company also plans to submit a marketing authorization application (MAA) for DUEXA in the European Union through the Decentralized Procedure in the second half of 2010.

About DUEXA

DUEXA is a novel, proprietary fixed-dose tablet combining the one of the world's most prescribed NSAIDs, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.  Ibuprofen has proven anti-inflammatory and analgesic properties, whereas famotidine reduces the stomach acid secretion that can cause gastric and duodenal ulceration.   By combining ibuprofen and famotidine into a single product, it is believed that ibuprofen's gastrointestinal safety profile will be improved without altering its ability to reduce pain and inflammation.

About the Arthritis and Pain Market

According to the Arthritis Foundation, arthritis affects 46 million people in the U.S. and costs the U.S. economy $128 billion annually.  According to a study by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup, due to the increasing aging population, arthritis is projected to increase by 40 percent in the next two decades.  The CDC estimates that 67 million people in the U.S. will be affected by arthritis by 2030.  Additionally, chronic pain affects an estimated 86 million American adults. NSAIDs are among the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced.  Because the prostaglandins that protect the stomach are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations annually in the U.S. alone.

Recently published data also indicates that physicians only co-prescribe GI protective agents 27 percent of the time.  In addition, historical data has shown that, by the third prescription, over 60 percent of patients stop taking their prescribed GI co-therapy.  

About Horizon Pharma

Horizon Pharma, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation.   Horizon's product portfolio includes innovative therapies in early- and late-stage development that are designed to improve the efficacy, safety and quality of life for patients with chronic pain and inflammation.   Horizon's most advanced product is LODOTRA, a circadian cytokine modulator (CCM) for the treatment of the signs and symptoms of rheumatoid arthritis (RA), which has received a recommendation for granting of a national marketing authorization in certain Member States of the European Union.  L ODOTRA is already launched in Germany.   The company's lead development stage product is DUEXA, a novel, proprietary fixed-dose tablet combining one of the most prescribed NSAIDs in the world, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.   In two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), DUEXA was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal (GI) ulcers in patients with mild-to-moderate pain and arthritis.   The Company is financed by leading life-science investors Atlas Venture, Deutsche Bank AG, London, Essex Woodlands Healthcare Ventures, FirstMark Capital, Global Life Science Ventures, NGN Capital, Scale Ventures, Sutter Hill Ventures and TVM Capital.

For more information about the company and its products, please visit www.horizonpharma.com.

Forward Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to, any statements regarding the future of any product or product candidate, including the timing of the submission of regulatory filings for approval of such products or product candidates and the timing of any regulatory approval; and any statements of the plans, strategies and objectives of management for future operations of the company.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, the inherent risks of product development and approval, clinical outcomes, regulatory risks, risks related to proprietary rights, market acceptance and competition and risks associated with the company's ability to obtain additional capital to support its planned operations.


'/>"/>
SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology:
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... program. MyDecision™ empowers employers and organizations with the tools and information to lower ... three elements to cut the cost of providing employee healthcare benefits by as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):